Sustained GH Stimulation
Single SC injection elevates GH 2–10× for 6+ days. Multi-dose protocols maintain IGF-1 above baseline for 28 days in healthy adults.
Teichman et al. 2006≥99% Purity
CJC-1295 DAC
A long-acting peptide that boosts your body's own growth hormone
$60.00$30.00/vial with BOGO
USA madecGMP facility
QuantityBuy 1 Get 1 Free · auto-appliedAdd 2+ items to cart to activate the discount
Free Shipping on orders over $200
PASSEDSterility & Endotoxins
PASSEDNet Content & Purity
Researchers also added
Authenticity
Every vial is QR-authenticated
Scan the QR code on any vial to verify its batch, COA, and origin in seconds. Secure traceability from our lab to your bench.
About this compound
CJC-1295 DAC is a long-acting growth-hormone-releasing peptide. Its albumin-binding modification keeps it working for days, making it a well-studied option for sustained growth hormone and IGF-1 support.
Synthetic 30-amino-acid GHRH(1–29) analog with Drug Affinity Complex (DAC) albumin-binding modification
- Formula
- C152H252N44O42
- Molecular weight
- 3367.97 g/mol
- Form
- Lyophilized Powder
- CAS / ID
- 863288-34-0
0 days
Plasma Half-Life
5.8–8.1 days via albumin binding
0×
GH Elevation
2–10× above baseline for 6+ days
0 days
IGF-1 Elevation
Maintained above baseline (multi-dose)
0
Research Areas
Sustained GH Stimulation · Albumin-Depot Mechanism · GHRH Axis Selectivity & more
How It Works
How CJC-1295 DAC works
The pathways CJC-1295 DAC acts on — and what each one does. The animation traces its signal outward from the compound to every target it engages.
Signalling pathways studied in preclinical models · illustrative
GHRH Receptor Activation
GHRH-R Agonist
CJC-1295 DAC is a 30-amino acid analog of GHRH(1–29) with four strategic substitutions that confer protease resistance. It binds and activates GHRH receptors on pituitary somatotrophs, directly stimulating growth hormone synthesis and pulsatile release — the same signaling axis as endogenous GHRH, but massively extended.
- Selective GHRH receptor agonism
- Stimulates GH synthesis in somatotrophs
- Preserves pulsatile GH secretion pattern
Albumin Binding — Half-Life Extension
DAC Technology
The Drug Affinity Complex (DAC) is a maleimidopropionic acid group attached to Lys8 of the peptide. After injection, it covalently bonds to Cys34 of circulating serum albumin — eliminating DPP-IV cleavage and extending half-life from 7 minutes to 5.8–8.1 days. The albumin acts as a circulating depot, slowly releasing active peptide.
- Covalent bond to serum albumin Cys34
- Eliminates DPP-IV protease cleavage
- 1,650× longer half-life vs native GHRH
Downstream IGF-1 Elevation
IGF-1 Axis
Sustained GH elevation drives hepatic insulin-like growth factor-1 (IGF-1) production. IGF-1 mediates downstream effects and remains elevated 9–11 days from a single injection due to the sustained GH signal, with cumulative elevation demonstrated on multi-dose protocols.
- IGF-1 elevated 1.5–3× above baseline
- Sustained 9–11 days from single injection
- 28-day elevation on multi-dose protocol
Uses & Applications
What CJC-1295 DAC is researched for
The main areas CJC-1295 DAC is being studied for — and the study-reported figures behind them.
Albumin-Depot Mechanism
DAC covalently binds serum albumin Cys34, creating an endogenous depot. Half-life measured at 5.8–8.1 days — enabling once-weekly administration in research protocols.
Teichman et al. 2006GHRH Axis Selectivity
Cortisol, thyroid hormones, and prolactin remain unaffected across all doses tested — confirming selective GHRH receptor agonism without hypothalamic–pituitary–adrenal axis activation.
Teichman et al. 2006Growth Normalization
Once-daily CJC-1295 normalized growth in GHRH knockout mice, demonstrating in vivo GHRH receptor replacement activity with favorable tolerability in rodent models.
Alba et al. 2006Molecular Structure
The CJC-1295 DAC molecule
An interactive 3D model rendered from the compound record — rotate and explore its structure.
C152H252N44O42
How Long It Lasts
Duration & clearance
How CJC-1295 DAC clears from circulation, modeled from its documented ~5.8–8.1 days (albumin-bound) half-life. The curve draws as you scroll.
CJC-1295 DAC · ~5.8–8.1 days (albumin-bound)
Reference · rapid clearance
Third-Party Verified
Independently tested. Verifiably pure.
Every batch of CJC-1295 DAC is sent to an accredited independent laboratory before it ships. Here is what we screen for.
- HPLC Purity AnalysisConfirms the peptide is ≥99% pure
- Mass SpectrometryVerifies the exact molecular identity
- Heavy Metals ScreeningLead, arsenic, cadmium & mercury — Pass
- Endotoxins (LAL)Bacterial endotoxin levels — Pass
- Sterility TestingNo microbial contamination — Pass
- Net Peptide ContentActual peptide mass per vial verified
Certificate of Analysis · Freedom DiagnosticPASS
- HPLC Purity
- ≥99%
- Identity
- Mass-spec confirmed
- Endotoxin (LAL)
- Pass
- Net content
- Verified
Compound Information
Full specification
| Also Known As | DAC:GRF, CJC-1295 with DAC |
| Type | Synthetic GHRH analog with Drug Affinity Complex |
| CAS Number | 863288-34-0 |
| Molecular Weight | 3,647.1 g/mol |
| Amino Acids | 30 (GHRH 1–29 analog) |
| DAC Modification | Maleimidopropionic acid on Lys8 → covalent albumin Cys34 binding |
| Plasma Half-Life | 5.8–8.1 days (albumin-bound) |
| Form | Lyophilized powder |
| Purity | ≥99% (HPLC verified) |
| Testing | Third-party HPLC, Mass Spec, Endotoxin |
| Storage (Lyophilized) | -20°C for up to 24 months |
| Storage (Reconstituted) | 2–8°C, use within 28 days |
| Solubility | Bacteriostatic water for reconstitution |
| COA | Included with every order |
| Strength | 5mg |
| Molecular Formula | C152H252N44O42 |
| Appearance | White to off-white powder |
FAQ
Common questions about CJC-1295 DAC
CJC-1295 DAC (also called DAC:GRF) is a 30-amino acid synthetic analog of growth hormone-releasing hormone (GHRH) with a Drug Affinity Complex (DAC) modification — a maleimidopropionic acid group at Lys8. After injection, this group covalently bonds to Cys34 of circulating serum albumin. Albumin acts as a circulating depot, slowly releasing active peptide and extending the half-life from ~7 minutes (native GHRH) to 5.8–8.1 days.
Teichman et al. (JCEM 2006) conducted two randomized, double-blind, placebo-controlled trials in 57 healthy adults (ages 21–61). Results: a single 30–60 µg/kg SC injection elevated GH 2–10× above baseline for 6+ days and IGF-1 by 1.5–3× for 9–11 days. Multi-dose protocols (2–3 weekly/biweekly injections) maintained IGF-1 above baseline for up to 28 days with a cumulative effect. No serious adverse events were reported.
The sole structural difference is the DAC modification. CJC-1295 without DAC (Modified GRF 1-29, "Mod GRF") has a half-life of approximately 20–30 minutes and must be administered multiple times daily for sustained GH stimulation. CJC-1295 DAC's albumin binding extends the half-life to ~8 days — enabling once-weekly dosing while preserving the same GHRH receptor selectivity.
No. CJC-1295 DAC acts selectively on the GHRH receptor on pituitary somatotrophs. Clinical trial data confirmed that cortisol, thyroid hormones (T3, T4, TSH), and prolactin were unaffected across all doses tested. This selectivity distinguishes it from non-selective GH secretagogues such as GHRP-6 and hexarelin, which elevate cortisol and prolactin as known side effects.
No. CJC-1295 DAC was developed by ConjuChem Biotechnologies (Canada). Phase 1/2 trials were completed in 2006, but Phase 3 development was never pursued after the company dissolved. It has never received FDA approval and is classified as a research compound. It is sold for in vitro research purposes only and is not intended for human therapeutic use.
Lyophilized (powder) form should be stored at -20°C for up to 24 months. Once reconstituted with bacteriostatic water, store at 2–8°C and use within 28 days. Avoid repeated freeze-thaw cycles and protect from light and heat. The DAC modification does not significantly affect peptide stability in lyophilized form.
Published Literature
Cited Sources
Peer-reviewed literature
Independent published research indexed from PubMed and peer-reviewed journals — not Eon Peptides claims.
[1]
PubMed
[2]Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting analog of GHRH, in healthy adults
View source PubMed
[3]Once-daily administration of CJC-1295 normalizes growth in the GHRH knockout mouse
View source PubMed
[4]Drug Affinity Complex technology: extending peptide half-life via covalent albumin binding
View source PubMed
GHRH analog sermorelin and CJC-1295 pharmacodynamic comparison in GH deficiency models
View source For Research Use Only.
Not for human or veterinary use. For in-vitro laboratory research only. These statements have not been evaluated by the FDA; this product is not intended to diagnose, treat, cure, or prevent any disease. Sold exclusively to qualified researchers and institutions.